论文部分内容阅读
目的:探讨与进展期胃癌对替吉奥胶囊联合奥沙利铂(SOX)新辅助化疗敏感性有关的基因及信号通路。方法:收集15例III期胃癌患者术后标本,其中6例SOX新辅助化疗后缓解(缓解组)、6例SOX新辅助化疗后未缓解(未缓解组),3例未行新辅助化疗(未化疗组),在用高通量基因芯片法检测各组标本基因表达谱后,以DNA损伤修复和叶酸代谢方面为重点分析对象,用系统性生物信息学技术筛选出差异基因,并通过KEGG来解释每个差异表达基因所在通路。结果:3组标本的基因表达谱存在明显差异。缓解组与未缓解组间的差异基因主要集中在细胞因子相互作用和NK细胞介导的细胞毒性作用通路上。与未缓解组比较,缓解组与DNA损伤修复相关的3个基因(HUS1、RECQL5、XRCC4)明显上调和1个基因(GADD45G)明显下调;3组间在叶酸代谢方面未找到任何差异基因。结论:影响进展期胃癌SOX新辅助化疗敏感性的基因可能与免疫信号传导有关,相关的基因检测对评估胃癌SOX新辅助化疗效果有一定的意义。
OBJECTIVE: To investigate the gene and signal pathways involved in the sensitivity of neoadjuvant chemotherapy with tioggio capsules and oxaliplatin (SOX) in advanced gastric cancer. Methods: Fifteen patients with stage III gastric cancer were collected postoperatively. Six patients were relieved after neoadjuvant chemotherapy (remission group), six without remission after neoadjuvant chemotherapy (unrelated group) and three without neoadjuvant chemotherapy Non-chemotherapy group). After the gene expression profiles of each group were detected by high-throughput gene chip method, DNA damage repair and folic acid metabolism were the main analysis objects, and the differential genes were screened by systemic bioinformatics technology. To explain the pathways for each differentially expressed gene. Results: The gene expression profiles of three groups of specimens showed significant differences. Differences between the remission group and the non-remission group Genes mainly focused on cytokine interactions and NK cell-mediated cytotoxicity pathways. Three genes (HUS1, RECQL5, XRCC4) and one gene (GADD45G) were significantly upregulated in the remission group compared with those in the non-remission group. No difference in the folic acid metabolism was found among the three groups. CONCLUSIONS: The genes that affect the sensitivity of neoadjuvant chemotherapy in advanced gastric cancer may be related to the immune signaling. The related genetic tests may be of some value in assessing the efficacy of neoadjuvant chemotherapy for gastric cancer.